公开(公告)号：US20250144209A1

公开(公告)日：2025-05-08

申请号：US19014653

申请日：2025-01-09

Applicant: Alector LLC

Inventor： Andrew Pincetic ,  Arnon Rosenthal ,  Seung-Joo Lee

IPC: A61K39/395 ,  A61P31/00 ,  A61P35/00 ,  C07K16/28

Abstract: The invention provides anti-SIRPA antibodies, methods of generating such antibodies, and therapeutic uses and methods employing the antibodies.

公开(公告)号：US12258410B2

公开(公告)日：2025-03-25

申请号：US18627754

申请日：2024-04-05

Applicant: Alector LLC

Inventor： Andrew Pincetic ,  Wei-Hsien Ho ,  Patricia Culp ,  Arnon Rosenthal

IPC: C07K16/28 ,  C07K16/24 ,  C07K16/40 ,  C07K16/42 ,  C12N15/85

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPA polypeptide, e.g., a mammalian SIRPA or human SIRPA, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US12110327B2

公开(公告)日：2024-10-08

申请号：US17931757

申请日：2022-09-13

Applicant: Alector LLC

Inventor： Andrew Pincetic ,  Arnon Rosenthal ,  Helen Lam ,  Francesca Avogadri-Connors ,  Seung-Joo Lee

IPC: C07K16/28

CPC classification number: C07K16/2803 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/80 ,  C07K2317/92

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM1 protein, e.g., a mammalian TREM1 or human TREM1, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20240174746A1

公开(公告)日：2024-05-30

申请号：US18551162

申请日：2022-03-17

Applicant: ALECTOR LLC

Inventor： Eric BROWN ,  Angie Grace YEE ,  Tina SCHWABE ,  Herve RHINN ,  Arnon ROSENTHAL

IPC: C07K16/28 ,  A61K39/00

CPC classification number: C07K16/28 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/76

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, antibody fragments, etc., that specifically bind a TMEM106B polypeptide, e.g., a mammalian TMEM106B or human TMEM106B, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20240101681A1

公开(公告)日：2024-03-28

申请号：US18039945

申请日：2021-12-01

Applicant: Alector LLC

Inventor： Arnon ROSENTHAL ,  Felix Leejia YEH ,  Michael F. WARD ,  Robert PAUL ,  Hua LONG ,  Yijie LIAO

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06

CPC classification number: C07K16/286 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505

Abstract: The present disclosure is generally directed to the use of antibodies that specifically bind one or more epitopes within a sortilin protein, e.g., human sortilin or mammalian sortilin, for treating and/or delaying progression of a disease, disorder, or injury in an individual in need thereof.

公开(公告)号：US20240067723A1

公开(公告)日：2024-02-29

申请号：US18298110

申请日：2023-04-10

Applicant: Alector LLC

Inventor： Arnon Rosenthal ,  Kate Monroe ,  Seung-Joo Lee

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61P25/00 ,  A61P29/00 ,  A61P31/04 ,  A61P35/00

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61K45/06 ,  A61P25/00 ,  A61P29/00 ,  A61P31/04 ,  A61P35/00 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20230295297A1

公开(公告)日：2023-09-21

申请号：US18171291

申请日：2023-02-17

Applicant: Alector LLC

Inventor： Tina SCHWABE ,  Fracesca AVOGADRI-CONNORS ,  Helen LAM ,  Ilaria TASSI ,  Seung-Joo LEE ,  Arnon ROSENTHAL

IPC: C07K16/28 ,  A61P25/28

CPC classification number: C07K16/2803 ,  A61P25/28 ,  A61K2039/505

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20230220074A1

公开(公告)日：2023-07-13

申请号：US17904513

申请日：2021-02-17

Applicant: Alector LLC

Inventor： Spencer LIANG ,  Samuel NALLE ,  Ling LEUNG

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2803 ,  A61P35/00 ,  C07K16/2827 ,  C07K2317/76 ,  A61K2039/507

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human PILRA and compositions comprising such antibodies or antigen-binding fragments thereof. In a particular aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human PILRA block binding of PILRA to ligand and/or decrease cell surface PILRA. In further aspects, the antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with myeloid cell dysfunction.

公开(公告)号：US11634489B2

公开(公告)日：2023-04-25

申请号：US16835140

申请日：2020-03-30

Applicant: Alector LLC

Inventor： Tina Schwabe ,  Eric Brown ,  Philip Kong ,  Ilaria Tassi ,  Seung-Joo Lee ,  Arnon Rosenthal ,  Robert Pejchal ,  Nels P. Nielson

IPC: A61P25/28 ,  A61K39/00 ,  C07K16/28

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20230047941A1

公开(公告)日：2023-02-16

申请号：US17836644

申请日：2022-06-09

Applicant: Alector LLC

Inventor： Tina SCHWABE ,  Michael KURNELLAS ,  Arnon ROSENTHAL ,  Robert PEJCHAL ,  Anthony B. COOPER

IPC: C07K16/28

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.